PTC Therapeutics, Inc. (NASDAQ:PTCT) is among the most profitable biotech stocks to buy. On October 20, Financial institution of America Securities analyst Tazeen Ahmad maintained a Purchase ranking on PTC Therapeutics, Inc. (NASDAQ:PTCT), lifting the value goal on the inventory to $87 from $76.
The analyst cited the strong preliminary demand for Sephience, which is the corporate’s newly permitted therapy. A notable curiosity might be seen within the therapy based on a survey of geneticists and neurologists treating PKU sufferers, with a number of of them already prescribing it and anticipating an increase in prescriptions within the close to future.
Ahmad acknowledged that this early uptake is particularly notable amongst sufferers who didn’t reply nicely to present therapies resembling Kuvan. He additionally cited the promising early tendencies in payor protection, with a excessive share of preliminary prescriptions being lined.
PTC Therapeutics, Inc. (NASDAQ:PTCT) is a biopharmaceutical firm that discovers, develops, and commercializes clinically differentiated medicines offering advantages to sufferers dwelling with uncommon problems.
Whereas we acknowledge the potential of PTCT as an funding, we imagine sure AI shares provide better upside potential and carry much less draw back threat. When you’re searching for an especially undervalued AI inventory that additionally stands to learn considerably from Trump-era tariffs and the onshoring pattern, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This text is initially revealed at Insider Monkey.
